Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
H&R Block's e-filing products are intuitive and easy to use. For paid users, tax pro support is available via screen share or chat. Many, or all, of the products featured on this page are from our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results